TNFSF4 and cancer: Lastly, the integrationof a checkpoint inhibitor (anti-PD-1 antibody) or immunomodulator(OX40L) into the hydrogel reprograms the immunosuppressive tumor microenvironment(TME), further potentiating the efficacy of the in situ cancer vaccination.